“The Oct. 15, 2019 trial date for Winston v. Monsanto in St. Louis City has been postponed,” Bayer said in a statement.
The lawsuit is the latest of several to be delayed as mediator Ken
Feinberg tries to negotiate a settlement between the company and U.S.
plaintiffs after a California jury in August last year found that
Monsanto should have warned of alleged cancer risks.
“With the change in the trial schedule and no trial dates set through
the rest of the year, the appeals of the three completed trials will be
a significant focus of the litigation in the months ahead,” Bayer said.
Handelsblatt first reported the latest delay earlier on Sunday.
A court document from the Circuit Court of the City of St. Louis,
dated October 4, said a status conference to reevaluate the case had
been set for February 10.
The number of U.S. plaintiffs blaming Roundup and other
glyphosate-based weed killers for cancer has been rising continuously to
stand at 18,400 as of July 11, hitting Bayer’s share price.
https://www.marketscreener.com/news/Bayer-says-Oct-U-S-glyphosate-trial-delayed-until-further-notice–29341536/?countview=0
Tuesday, October 8, 2019
Gilead Sciences submits NDA for filgotinib in Japan
Gilead Sciences (NASDAQ:GILD) submits
NDA for filgotinib, an investigational, oral, selective JAK1 inhibitor
for the treatment of adults with rheumatoid arthritis (RA) to the
Japanese Ministry of Health, Labor and Welfare.
Filgotinib is an investigational agent and is not
approved anywhere globally. Its efficacy and safety have not been
established by any regulatory authorities.
https://seekingalpha.com/news/3504383-gilead-sciences-submits-nda-filgotinib-japanPremarket analyst action
ChromaDex (NASDAQ:CDXC) initiated with Outperform rating and $8 (119% upside) price target at Sturdivant.
Satsuma Pharmaceuticals (NASDAQ:STSA) initiated with Outperform rating at both Evercore ISI and SVB Leerink.
SpringWorks Therapeutics (NASDAQ:SWTX)
initiated with Buy rating and $37 (89% upside) price target at Goldman
Sachs. Initiated with Outperform rating at Cowen and Company. Initiated
with Outperform rating and $33 price target at Wedbush. Initiated with
Outperform rating at JPMorgan.
QIAGEN (NYSE:QGEN) downgraded to Underweight with a $25 (22% downside risk) price target at JPMorgan after the company announced lower-than-expected preliminary sales growth for Q3 after the close yesterday. Shares down 19% premarket.
Nektar Therapeutics (NASDAQ:NKTR) downgraded to Sell with a $16 (14% downside risk) price target at Goldman. Shares down 6% premarket.
Puma Biotechnology (NASDAQ:PBYI) downgraded to Sell with an $8 (21% downside risk) price target at Goldman. Shares down 4% premarket.
https://seekingalpha.com/news/3504397-jpmorgan-downgrades-qiagen-premarket-analyst-actionFDA OKs Novartis’ Beovu for wet AMD
The FDA approves Novartis’ (NYSE:NVS) BEOVU (brolucizumab-dbll) injection (formerly RTH258) for the treatment of wet age-related macular degeneration (wet AMD).
The company says it offers greater fluid resolution than Regeneron Pharmaceuticals’ (NASDAQ:REGN) EYLEA (aflibercept) injection and a three-month maintenance dosing interval.
Brolucizumab, a humanized single-chain antibody
fragment with high affinity for all VEGF-A isoforms, demonstrated
non-inferiority to EYLEA in best corrected visual acuity while showing
superiority in key retinal outcomes at year one in Phase 3 studies.
NVS is down 1% premarket on light volume.
https://seekingalpha.com/news/3504401-fda-oks-novartis-beovu-wet-amdMonday, October 7, 2019
FDA Action Alert: Flexion, Alexion and Clearside
There are several scheduled PDFUA dates for the U.S. Food and Drug Administration (FDA) over the next two weeks. Here’s a look.
Flexion’s Zilretta for Osteoporosis of the Knee
Flexion Therapeutics has a target action date of October 14 for its supplemental NDA to revise the label for Zilretta to allow for repeat administration. This sNDA was based on an open-label Phase IIIb clinical trial of Zilretta in patients with osteoarthritis (OA) of the knee. It showed that repeat dosing of the drug for OA knee pain was generally safe and well-tolerated with no deleterious impact on cartilage or joint structure as seen on x-rays. The trial also found that the amount and duration of pain relief was similar in the first and second injections.
Zilretta launched in the fourth quarter of 2017. It is the first and only extended-release, intra-articular therapy for OA-related knee pain. It uses the company’s proprietary microsphere technology combined with triamcinolone acetonide, a common short-acting corticosteroid with a poly lactic-co-glycolic acid (PLGA) matrix that provides extended pain relief.
Alexion Pharmaceuticals’ Ultomiris for aHUS
Alexion Pharmaceuticals has a target action date of October 19 for its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). aHUS is a severe and chronic ultra-rare disease that can cause progressive damage to the organs, primarily the kidneys, which can lead to kidney failure and premature death.
Ultomiris is approved to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH).
The sBLA is based on data from the Phase III trial of the drug announced in January 2019. In the first 26-week treatment period, 53.6% of patients showed complete thrombotic microangiopathy (TMA) response. The primary endpoint of complete TMA response was defined by hematologic normalization and improved kidney function.
The sBLA is being evaluated under Priority Review.
Clearside Biomedical’s Xipere for Macular Edema
Clearside Biomedical has a target action date of October 19 for its NDA for Xipere (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for macular edema associated with uveitis. The NDA is based on data from the PEACHTREE clinical trial that showed significant and clinically meaningful improvement in eyesight for patients with macular edema associated with non-infectious uveitis. Uveitis is a group of ocular inflammatory conditions and one of the leading causes of vision loss. It affects about 350,000 people in the U.S. and more than a million worldwide. Macular edema is an accumulation of fluid in the macula, the area of the retina that accounts for sharp, straight-ahead vision.
However, on August 22, the company received an update about the NDA from the FDA’s Office of Pharmaceutical Quality (OPQ) requesting more stability data for the TA suspension that uses an enhanced manufacturing process. The TA formulation hadn’t changed, but the OPQ requested data to verify comparability of the stability profiles from several batches submitted as part of the NDA.
As a result, the company expects to receive a Complete Response Letter from the FDA on or before October 19. It will then resubmit the NDA in the first quarter of 2020 with the requested stability data.
“We believe this is primarily a timing issue since our stability data from previously manufactured batches have been consistent and predictable, and we have every reason to believe this will continue to be the case,” stated George Lasezkay, Clearside’s chief executive officer, in an August statement.
https://www.biospace.com/article/fda-action-alert-pfenex-flexion-alexion-and-clearside/
Flexion’s Zilretta for Osteoporosis of the Knee
Flexion Therapeutics has a target action date of October 14 for its supplemental NDA to revise the label for Zilretta to allow for repeat administration. This sNDA was based on an open-label Phase IIIb clinical trial of Zilretta in patients with osteoarthritis (OA) of the knee. It showed that repeat dosing of the drug for OA knee pain was generally safe and well-tolerated with no deleterious impact on cartilage or joint structure as seen on x-rays. The trial also found that the amount and duration of pain relief was similar in the first and second injections.
Zilretta launched in the fourth quarter of 2017. It is the first and only extended-release, intra-articular therapy for OA-related knee pain. It uses the company’s proprietary microsphere technology combined with triamcinolone acetonide, a common short-acting corticosteroid with a poly lactic-co-glycolic acid (PLGA) matrix that provides extended pain relief.
Alexion Pharmaceuticals’ Ultomiris for aHUS
Alexion Pharmaceuticals has a target action date of October 19 for its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). aHUS is a severe and chronic ultra-rare disease that can cause progressive damage to the organs, primarily the kidneys, which can lead to kidney failure and premature death.
Ultomiris is approved to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH).
The sBLA is based on data from the Phase III trial of the drug announced in January 2019. In the first 26-week treatment period, 53.6% of patients showed complete thrombotic microangiopathy (TMA) response. The primary endpoint of complete TMA response was defined by hematologic normalization and improved kidney function.
The sBLA is being evaluated under Priority Review.
Clearside Biomedical’s Xipere for Macular Edema
Clearside Biomedical has a target action date of October 19 for its NDA for Xipere (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for macular edema associated with uveitis. The NDA is based on data from the PEACHTREE clinical trial that showed significant and clinically meaningful improvement in eyesight for patients with macular edema associated with non-infectious uveitis. Uveitis is a group of ocular inflammatory conditions and one of the leading causes of vision loss. It affects about 350,000 people in the U.S. and more than a million worldwide. Macular edema is an accumulation of fluid in the macula, the area of the retina that accounts for sharp, straight-ahead vision.
However, on August 22, the company received an update about the NDA from the FDA’s Office of Pharmaceutical Quality (OPQ) requesting more stability data for the TA suspension that uses an enhanced manufacturing process. The TA formulation hadn’t changed, but the OPQ requested data to verify comparability of the stability profiles from several batches submitted as part of the NDA.
As a result, the company expects to receive a Complete Response Letter from the FDA on or before October 19. It will then resubmit the NDA in the first quarter of 2020 with the requested stability data.
“We believe this is primarily a timing issue since our stability data from previously manufactured batches have been consistent and predictable, and we have every reason to believe this will continue to be the case,” stated George Lasezkay, Clearside’s chief executive officer, in an August statement.
https://www.biospace.com/article/fda-action-alert-pfenex-flexion-alexion-and-clearside/
EU Panel: Don’t Use Estradiol Creams for Longer Than 4 Weeks
The European Medicines Agency’s Pharmacovigilance Risk Assessment
Committee (PRAC) recommends capping the use of high-strength creams that
contain estradiol 100 μg/g (0.01%) at a single treatment period of no longer than 4 weeks.
The reason for this recommendation is to lower the risk for adverse effects, such as blood clots, strokes, and certain types of cancer, which can result from absorption of estradiol into the bloodstream from intravaginal creams used to relieve vaginal atrophy symptoms in postmenopausal women.
The recommendation appears in highlights from the PRAC meeting held from September 30 to October 3.
The European Commission requested the review, which was initiated in April 2019, after a ruling by the European Union Court of Justice that “partially annulled the conclusions of a previous PRAC review of these medicines in 2014 on procedural grounds.”
The Court of Justice accepted the scientific conclusions; however, this partial annulment invalidated some of the measures implemented to reduce the risk.
The PRAC’s recommendation follows consideration of all available safety and efficacy data on high-strength estradiol-containing creams, including the amount of the hormone in the blood.
“These data showed that in postmenopausal women who had used these creams, the levels of estradiol in the blood were higher than normal postmenopausal levels,” according to the meeting highlights.
The new recommendations will be added to the prescribing information for these estradiol creams, along with a warning that they be used for no more than a single treatment period of no longer as 4 weeks. This warning will be on the outer and inner packaging, and the tube size will be no larger than 25 g to prevent more extended use than recommended.
https://www.medscape.com/viewarticle/919501
The reason for this recommendation is to lower the risk for adverse effects, such as blood clots, strokes, and certain types of cancer, which can result from absorption of estradiol into the bloodstream from intravaginal creams used to relieve vaginal atrophy symptoms in postmenopausal women.
The recommendation appears in highlights from the PRAC meeting held from September 30 to October 3.
The European Commission requested the review, which was initiated in April 2019, after a ruling by the European Union Court of Justice that “partially annulled the conclusions of a previous PRAC review of these medicines in 2014 on procedural grounds.”
The Court of Justice accepted the scientific conclusions; however, this partial annulment invalidated some of the measures implemented to reduce the risk.
The PRAC’s recommendation follows consideration of all available safety and efficacy data on high-strength estradiol-containing creams, including the amount of the hormone in the blood.
“These data showed that in postmenopausal women who had used these creams, the levels of estradiol in the blood were higher than normal postmenopausal levels,” according to the meeting highlights.
The new recommendations will be added to the prescribing information for these estradiol creams, along with a warning that they be used for no more than a single treatment period of no longer as 4 weeks. This warning will be on the outer and inner packaging, and the tube size will be no larger than 25 g to prevent more extended use than recommended.
https://www.medscape.com/viewarticle/919501
Immunotherapy-Induced Arthritis Persists Post-Cancer Therapy
Target Audience and Goal Statement:
Oncologists, rheumatologists, internists, family medicine specialists
The goal of this study was to determine the long-term outcomes of cancer patients treated with immune checkpoint inhibitors (ICIs) who developed inflammatory arthritis.
Question Addressed:
In cancer patients who developed arthritis during treatment with ICIs, joint symptoms were less likely to resolve in those with greater exposure to these drugs and in those treated with a combination of ICIs, a prospective observational study found.
Patients with a history of other immune-related adverse events also
had more persistent arthritis, according to Laura C. Cappelli, MD, and
colleagues from Johns Hopkins School of Medicine in Baltimore.
In a multivariate analysis, the likelihood of improvement in inflammatory arthritis was lower for patients with longer duration of ICI treatment, with a hazard ratio of 0.82 (95% CI 0.73-0.92, P=0.001), and for those on combination ICI regimens (HR 0.06, 95% CI 0.01-0.50, P=0.009), researchers reported online in Annals of the Rheumatic Diseases.
“This information provides insight into which individuals are at highest risk for developing persistent inflammatory arthritis, thus warranting close monitoring for joint-related symptoms, early referral to and close follow-up by rheumatology, and potentially more aggressive immunosuppressive therapy,” Cappelli’s group wrote.
As ICIs are increasingly used in treating a range of cancer types, researchers have seen the development of a number of inflammatory and autoimmune syndromes in patients during treatment, possibly through activation of T cells against antigens to the self, the researchers said. Some of these adverse events, such as pneumonitis and colitis, can be deadly, while others, such as inflammatory arthritis and thyroid dysfunction, can have profound and ongoing impact on patients’ function and quality of life. There have also been reports of the rapid appearance of erosions in affected patients.
Most patients who develop arthritis have required treatment with corticosteroids, other immunosuppressives, and even biologic agents, but it has been challenging to develop optimal strategies, given the context that their cancer treatment has involved immune activation. In addition, risk factors for the occurrence and persistence of arthritis have so far been unknown.
For this study, the researchers looked at the long-term outcomes of 60 patients who developed arthritis with ICI treatment. The team recruited patients from 2015 to 2018 who had been referred to the Johns Hopkins Arthritis Center and who had been given an anti-CTLA-4, anti-PD-1, or anti-PD-L1 agent, or a combination of these drugs. The average follow-up time was 12 months after stopping the ICI treatment.
Slightly more than half of the participants were women; mean age was 59 and most were white. The median Clinical Disease Activity Index at the time of recruitment was 17.5, which represents moderate activity. Duration of ICI treatment averaged 7 months, and half of patients had reported other immune-related events, most often colitis and rash.
The most common types of cancer treated in this population were melanoma and non-small cell lung cancer, and treatment outcomes included stable disease in 28.3% of patients, progressive disease in 25%, complete response in 23.3%, partial response in 16.7%, and no evidence of disease in 6.7%.
Follow-up data 3 months after cessation of ICI treatment were available for 51 patients, at which time 70.6% still had active arthritis. Among the 41 for whom 6-month data were available, 48.8% had persistent arthritis, and among the 20 patients who continued to have inflammatory arthritis at 6 months, 14 remained symptomatic during additional follow-up.
In a univariate analysis, factors associated with a decreased likelihood of improvements in arthritis were:
Three-quarters of patients were prescribed immunomodulatory treatment for their arthritis: corticosteroids in 48, conventional disease-modifying antirheumatic drugs (DMARDs) in 19, and biologics in 11.
Among the 24 patients who received either DMARDs or biologics, only four (16.7%) experienced cancer progression, which did not differ significantly from the rates of progression in patients not given these drugs (22.2%, OR 0.65, 95% CI 0.17-2.47).
A limitation of the study was the possibility of selection bias, acknowledged the researchers.
Source Reference: Annals of the Rheumatic Diseases 2019; DOI: 10.1136/annrheumdis-2019-216109
Study Highlights and Explanation of Findings:
This study confirms earlier smaller studies that indicated that inflammatory arthritis can remain active for months to years after treatment with ICIs ends. The authors noted that other immune-related adverse events that may occur or reoccur and become chronic after ICI cessation are pneumonitis, colitis, hepatitis, dermatitis, and neuropathy.
Previous studies of other types of immune-related adverse events have suggested that most develop during treatment induction, which does not appear to be the case with arthritis, the researchers said. “The kinetics of ICI-induced inflammatory arthritis development differs from many other immune-related adverse events, and may suggest unique immune pathogenesis for ICI-induced inflammatory arthritis, potentially due to longer exposure to ICI therapy.”
“Delayed initial presentation of [immune-related adverse events], with symptoms starting even after ICI cessation, is a related concept that is being increasingly recognized,” the authors wrote. “Further prospective cohort studies are needed to determine which [immune-related adverse events] besides [inflammatory arthritis] are likely to persist or present after ICI cessation.”
They added that the types of immune-related adverse events that persist “may indicate how the immune system interacts with particular target tissue microenvironments causing a feed forward loop of autoimmunity that becomes independent of ICIs.”
The researchers noted that like endocrine-related immune-related adverse events, ICI-induced inflammatory arthritis may need chronic treatment. The cited concern with using immunosuppression to treat these adverse events has been that they may negatively affect antitumor immune responses. Importantly, this study and a number of previous trials indicated that DMARDs and TNF inhibitors used to treat immune-related adverse events do not in fact affect antitumor responses.
Interestingly, the data suggest that patients who develop persistent arthritis may experience better antitumor responses compared with those who have transient arthritis. “Other studies have demonstrated that development of [immune-related adverse events] associates with better progression-free and overall survival, but persistence of an [immune-related adverse event] has not been examined,” the researchers wrote.
Further exploration of the biology of the various types of immune-related adverse events may help in determining more closely targeted therapeutic strategies for these conditions, they noted. “Overall, continued clinical and translational investigation on larger longitudinal cohorts will allow for increased understanding of pathophysiology and determination of the best clinical care for patients with ICI-induced inflammatory arthritis.”
Oncologists, rheumatologists, internists, family medicine specialists
The goal of this study was to determine the long-term outcomes of cancer patients treated with immune checkpoint inhibitors (ICIs) who developed inflammatory arthritis.
Question Addressed:
- What factors were associated with ICI-induced inflammatory arthritis persistence after treatment cessation?
In cancer patients who developed arthritis during treatment with ICIs, joint symptoms were less likely to resolve in those with greater exposure to these drugs and in those treated with a combination of ICIs, a prospective observational study found.
Action Points
- In cancer patients who developed inflammatory arthritis during treatment with immune checkpoint inhibitors (ICIs), joint symptoms were less likely to resolve in those with greater exposure to these drugs, those treated with a combination of ICIs, and those with a history of other immune-related adverse events, according to a prospective observational study.
- Understand that ICI-induced inflammatory arthritis can become a chronic condition in cancer patients, warranting close monitoring for joint-related symptoms, early referral to and close follow-up by rheumatologists, and potentially more aggressive immunosuppressive treatments.
In a multivariate analysis, the likelihood of improvement in inflammatory arthritis was lower for patients with longer duration of ICI treatment, with a hazard ratio of 0.82 (95% CI 0.73-0.92, P=0.001), and for those on combination ICI regimens (HR 0.06, 95% CI 0.01-0.50, P=0.009), researchers reported online in Annals of the Rheumatic Diseases.
“This information provides insight into which individuals are at highest risk for developing persistent inflammatory arthritis, thus warranting close monitoring for joint-related symptoms, early referral to and close follow-up by rheumatology, and potentially more aggressive immunosuppressive therapy,” Cappelli’s group wrote.
As ICIs are increasingly used in treating a range of cancer types, researchers have seen the development of a number of inflammatory and autoimmune syndromes in patients during treatment, possibly through activation of T cells against antigens to the self, the researchers said. Some of these adverse events, such as pneumonitis and colitis, can be deadly, while others, such as inflammatory arthritis and thyroid dysfunction, can have profound and ongoing impact on patients’ function and quality of life. There have also been reports of the rapid appearance of erosions in affected patients.
Most patients who develop arthritis have required treatment with corticosteroids, other immunosuppressives, and even biologic agents, but it has been challenging to develop optimal strategies, given the context that their cancer treatment has involved immune activation. In addition, risk factors for the occurrence and persistence of arthritis have so far been unknown.
For this study, the researchers looked at the long-term outcomes of 60 patients who developed arthritis with ICI treatment. The team recruited patients from 2015 to 2018 who had been referred to the Johns Hopkins Arthritis Center and who had been given an anti-CTLA-4, anti-PD-1, or anti-PD-L1 agent, or a combination of these drugs. The average follow-up time was 12 months after stopping the ICI treatment.
Slightly more than half of the participants were women; mean age was 59 and most were white. The median Clinical Disease Activity Index at the time of recruitment was 17.5, which represents moderate activity. Duration of ICI treatment averaged 7 months, and half of patients had reported other immune-related events, most often colitis and rash.
The most common types of cancer treated in this population were melanoma and non-small cell lung cancer, and treatment outcomes included stable disease in 28.3% of patients, progressive disease in 25%, complete response in 23.3%, partial response in 16.7%, and no evidence of disease in 6.7%.
Follow-up data 3 months after cessation of ICI treatment were available for 51 patients, at which time 70.6% still had active arthritis. Among the 41 for whom 6-month data were available, 48.8% had persistent arthritis, and among the 20 patients who continued to have inflammatory arthritis at 6 months, 14 remained symptomatic during additional follow-up.
In a univariate analysis, factors associated with a decreased likelihood of improvements in arthritis were:
- Longer duration of ICI treatment: HR 0.93 (95% CI 0.87-0.99, P=0.02)
- Combination therapy: HR 0.29 (95% CI 0.12-0.72, P=0.008)
- History of other immune-related events: HR 0.61 (95% CI 0.39-0.95, P=0.03)
Three-quarters of patients were prescribed immunomodulatory treatment for their arthritis: corticosteroids in 48, conventional disease-modifying antirheumatic drugs (DMARDs) in 19, and biologics in 11.
Among the 24 patients who received either DMARDs or biologics, only four (16.7%) experienced cancer progression, which did not differ significantly from the rates of progression in patients not given these drugs (22.2%, OR 0.65, 95% CI 0.17-2.47).
A limitation of the study was the possibility of selection bias, acknowledged the researchers.
Source Reference: Annals of the Rheumatic Diseases 2019; DOI: 10.1136/annrheumdis-2019-216109
Study Highlights and Explanation of Findings:
This study confirms earlier smaller studies that indicated that inflammatory arthritis can remain active for months to years after treatment with ICIs ends. The authors noted that other immune-related adverse events that may occur or reoccur and become chronic after ICI cessation are pneumonitis, colitis, hepatitis, dermatitis, and neuropathy.
Previous studies of other types of immune-related adverse events have suggested that most develop during treatment induction, which does not appear to be the case with arthritis, the researchers said. “The kinetics of ICI-induced inflammatory arthritis development differs from many other immune-related adverse events, and may suggest unique immune pathogenesis for ICI-induced inflammatory arthritis, potentially due to longer exposure to ICI therapy.”
“Delayed initial presentation of [immune-related adverse events], with symptoms starting even after ICI cessation, is a related concept that is being increasingly recognized,” the authors wrote. “Further prospective cohort studies are needed to determine which [immune-related adverse events] besides [inflammatory arthritis] are likely to persist or present after ICI cessation.”
They added that the types of immune-related adverse events that persist “may indicate how the immune system interacts with particular target tissue microenvironments causing a feed forward loop of autoimmunity that becomes independent of ICIs.”
The researchers noted that like endocrine-related immune-related adverse events, ICI-induced inflammatory arthritis may need chronic treatment. The cited concern with using immunosuppression to treat these adverse events has been that they may negatively affect antitumor immune responses. Importantly, this study and a number of previous trials indicated that DMARDs and TNF inhibitors used to treat immune-related adverse events do not in fact affect antitumor responses.
Interestingly, the data suggest that patients who develop persistent arthritis may experience better antitumor responses compared with those who have transient arthritis. “Other studies have demonstrated that development of [immune-related adverse events] associates with better progression-free and overall survival, but persistence of an [immune-related adverse event] has not been examined,” the researchers wrote.
Further exploration of the biology of the various types of immune-related adverse events may help in determining more closely targeted therapeutic strategies for these conditions, they noted. “Overall, continued clinical and translational investigation on larger longitudinal cohorts will allow for increased understanding of pathophysiology and determination of the best clinical care for patients with ICI-induced inflammatory arthritis.”
Reviewed by Henry A. Solomon, MD, FACP, FACC Clinical Associate Professor, Weill Cornell Medical College
Primary Source
Annals of the Rheumatic Diseases
Secondary Source
MedPage Today
Source Reference: Walsh N “ICI-Linked Arthritis: Risks for Persistence” 2019.
https://www.medpagetoday.org/rheumatology/arthritis/82546?_ga=2.252979721.1081251847.1570409347-265074527.1569866268
Subscribe to:
Posts (Atom)